Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zarion Pharmaceuticals
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Zarion Pharmaceuticals developed DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analogue, targeting rare diseases such as Allan-Herndon-Dudley syndrome. The program received Orphan Drug status in the US and reached Phase II clinical trials before being discontinued. There are no active clinical programs or evidence of ongoing operations as of the latest available updates.
- Therapeutic areas
- CardiovascularRare Diseases
- Modalities
- small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on Zarion Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zarion Pharmaceuticals.